N4 Pharma Plc (AIM: N4P), provide details of its work plan following the encouraging data from its oncology research as announced on 13 December 2021. The company sounded very positive
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide details of its work plan following
JPMorgan economists said Friday that international oil prices could rise to $150 per barrel in the first quarter of 2022 if there is a conflict between Russia and Ukraine.
Braveheart Investment Group plc (AIM: BRH), is pleased to provide the following update on Paraytec, a company within the Group’s investment portfolio. Recent upgrades to the CX300 instrument indicate a
First volunteers inoculated with Malaria human challenge virus
A surge in demand, fading omicron concerns, and OPEC+’s inability to increase output have all contributed to an impressive rally in oil prices.
Omega (AIM: ODX), the medical diagnostics company focused on Global Health (CD4 and COVID-19) and Health and Nutrition, announces that Colin King, Chief Executive Officer, has notified the Board that
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms announces that the next pre|CISIONTM
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of cancers and inflammation, announces that it has progressed discussions with the
The government stimulus of trillions of dollars and rock-bottom rates helped to boost the prices of digital assets. They are essential for the market’s stability.
Oil prices rose to above $78 per barrel Monday. This was due to tight supply and the hopes of a further demand recovery by 2022.
